Halozyme Therapeutics, Inc. Price & Performance (HALO)

Halozyme Therapeutics has announced FDA approval of VYVGART Hytrulo prefilled syringe, co-formulated with its ENHANZE technology, for self-injection in adults with generalized myasthenia gravis and CIDP. This marks the tenth approved partner product using ENHANZE, streamlining patient care with faster, at-home administration options.12

Short interest in Halozyme Therapeutics fell by 8.44% in March, now standing at 9.22 million shares or 7.54% of the float. The decrease suggests improving investor confidence, with the short interest ratio at 6.3 days to cover, below the threshold typically indicating widespread pessimism.34

Halozyme Therapeutics’ stock price has surged nearly 52% over the past year, significantly outperforming the broader healthcare sector. The company reported strong earnings growth in 2024, with a net profit margin above 43%, and maintains a market capitalization of $7.3 billion as of April 18, 2025.53